Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.

导出 OA

翻译打印收藏纠错

作者： Neal D,Bhatia ^[1] ; David M,Pariser ^[2] ; Leon,Kircik ^[3] ; Tina,Lin ^[4] ; Susan,Harris ^[5] ; Lindsey,Mathew ^[1] ; Radhakrishnan,Pillai ^[2]

作者单位： Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. ^[1] Dr. Pariser is with Virginia Clinical Research, Inc. in Norfolk, Vriginia. ^[2] Dr. Kircik is with the Indiana University School of Medicine in Indianapolis, Indiana; Physicians Skin Care, PLLC in Louisville, Kentucky, and the Icahn School of Medicine at Mount Sinai in New York, New York. ^[3] Dr. Lin is with Ortho Dermatologics in Bridgewater, New Jersey. Mses. Harris and Mathew are with Bausch Health in Bridgewater, New Jersey. ^[4] Dr. Pillai is with Dow Pharmaceutical Sciences Inc. in Petaluma, California. ^[5]

关键词 Psoriasis clinical trial halobetasol tazarotene topical

PMID 30588269

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交